Hip OANCT07883395
Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
An observational study of Hip OA, run by Meiji Pharma Spain S.A. at 4 sites in Spain.
Trial summary
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Hip OA
- How many people
- 40 participants
- Where
- 4 sitesSpain
- Study dates
- 29 Jan 2026to Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult outpatients (>40 years) with symptomatic hip osteoarthritis (Kellgren-Lawrence II-III) receiving intra-articular hyaluronic acid.
Who may be able to join
- Age: >40 years at the time of study inclusion
- Preserved gait capability, with or without assistive devices
- Symptomatic hip arthropathy with a disease evolution of at least 1 year.
- Radiographic Kellgren-Lawrence grade II-III documented within the 12 months prior to study entry
- Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score >15
- Patient currently receiving intra-articular hyaluronic acid treatment within 3 months prior to study inclusion
Who cannot join
- Refusal to provide written informed consent
- Females who are pregnant, breastfeeding, or not using effective contraception
- Body Mass Index (BMI) ≥ 30 kg/m²
- Presence of other chronic or autoimmune diseases that could interfere with clinical evaluation
- History of hypersensitivity or allergy to hyaluronic acid or its derivatives
- Prior administration of intra-articular platelet-rich plasma (PRP) or intra-articular corticosteroids within 3 months, or intra-articular hyaluronic acid within 6 months prior to study entry
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Spain4 sites, 4 recruiting
- Recruiting
Hospital Universitario de La Princesa
Madrid
Dr. J Del Río, +34 915 202 282, juliandel.rio@salud.madrid.org
- Recruiting
Hospital Universitario de La Princesa
Madrid
Dr. MJ Arriaza, +34 915 20 22 00, mariajose.arriaza@salud.madrid.org
- Recruiting
QuironSalud. Hospital Juan Bravo
Madrid
Dr. J Del Río, +34 910 687 999, julian.delrio@quironsalud.es
- Not yet recruiting
Hospital Provincial Nuestra Señora de Gracia
Zaragoza
Dr. A Santamaría, +34 976 44 00 22, asantamariato@salud.aragon.es
About this study
Official title: Clinical Follow-up Study of Patients With Hip Osteoarthritis Treated With Intra-Articular Hyaluronic Acid
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.
- Conditions
- Hip OA
- Keywords
- hip osteoarthritis, hyaluronic acid, intraarticular injection, Viscosupplementation
- Medical subject headings
- Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Hyaluronic acid (HA) | Patients with hip osteoarthritis treated with HA under real-world clinical practice conditions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in self-reported hip pain severityu as measured by Visual Analog Scale (VAS) Pain Score at 12 months
Assessment of patient-reported hip pain severity on a VAS, consisting of a 100mm horizontal line ranging from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate greater pain intensity; a negative change score reflects pain reduction.
Measured: Baseline (pre-treatment), 3 months and 12 months post-treatment
Secondary outcomes (4)
Change from Baseline in hip osteoarthritis symptoms as measured by WOMAC Osteoarthritis Index Total Score
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) evaluating hip pain, stiffness, and physical function. Total score ranges from 0 to 96 points, where higher scores indicate worse symptom severity and greater physical disability.
Measured: Baseline, Month 3, and Month 12
Change from Baseline in hip joint function as measured by Modified Harris Hip Score (mHHS)
Clinician- and patient-assessed standardized scale evaluating hip joint pain, gait, daily activities, and range of motion. Total score ranges from 0 to 100 points, where higher scores indicate superior hip joint function.
Measured: Baseline, Month 3, and Month 12
Change from Baseline in health-related quality of life as measured by the 12-Item Short Form Health Survey (SF-12)
Assessment of physical and mental health-related quality of life dimensions using the 12-Item Short Form Health Survey (SF-12). Standardized scores range from 0 to 100 points, where higher scores represent better health-related quality of life.
Measured: Baseline and Month 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participants experiencing adverse events and serious adverse events related or unrelated to intra-articular hyaluronic acid treatment throughout the follow-up period.
Measured: From baseline up to Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start29 Jan 2026
- Primary completionApr 2027 (estimated)
- Study completionApr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hip OAStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Meiji Pharma Spain S.A.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Quironsalud, Hospital Provincial Nuestra Señora de Gracia
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07883395
- Sponsor's protocol ID
- MPS-ADAP/03
- Status last verified
- Oct 2026
- First submitted
- 25 Sep 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Follow-up Study of Patients With Hip Osteoarthritis Treated With Intra-Articular Hyaluronic Acid
- ClinicalTrials.gov ID
- NCT07883395
- Acronym / sponsor ID
- MPS-ADAP/03
- Conditions
- Hip OA
- Keywords
- hip osteoarthritis, hyaluronic acid, intraarticular injection, Viscosupplementation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Meiji Pharma Spain S.A.Industry (pharma, biotech, devices)
- Collaborators
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa, Quironsalud, Hospital Provincial Nuestra Señora de Gracia
- Study start
- 29 Jan 2026 (actual)
- Primary completion
- Apr 2027 (estimated)
- Study completion
- Apr 2027 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study population consists of approximately 40 adult outpatients aged 40 years or older with symptomatic hip osteoarthritis of at least 1 year of clinical evolution, treated with intra-articular hyaluronic acid in routine clinical practice within the Traumatology and Rehabilitation departments of participating hospitals in Spain.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hyaluronic acid (HA) | – | –Patients with hip osteoarthritis treated with HA under real-world clinical practice conditions |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult outpatients (>40 years) with symptomatic hip osteoarthritis (Kellgren-Lawrence II-III) receiving intra-articular hyaluronic acid.
Key inclusion criteria (6 listed)
- Age: >40 years at the time of study inclusion
- Preserved gait capability, with or without assistive devices
- Symptomatic hip arthropathy with a disease evolution of at least 1 year.
- Radiographic Kellgren-Lawrence grade II-III documented within the 12 months prior to study entry
- Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score >15
Key exclusion criteria (6 listed)
- Refusal to provide written informed consent
- Females who are pregnant, breastfeeding, or not using effective contraception
- Body Mass Index (BMI) ≥ 30 kg/m²
- Presence of other chronic or autoimmune diseases that could interfere with clinical evaluation
- History of hypersensitivity or allergy to hyaluronic acid or its derivatives
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change from Baseline in self-reported hip pain severityu as measured by Visual Analog Scale (VAS) Pain Score at 12 months
Time frame: Baseline (pre-treatment), 3 months and 12 months post-treatment
Assessment of patient-reported hip pain severity on a VAS, consisting of a 100mm horizontal line ranging from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate greater pain intensity; a negative change score reflects pain reduction.
4 secondary outcomes
Change from Baseline in hip osteoarthritis symptoms as measured by WOMAC Osteoarthritis Index Total Score
Time frame: Baseline, Month 3, and Month 12
Change from Baseline in hip joint function as measured by Modified Harris Hip Score (mHHS)
Time frame: Baseline, Month 3, and Month 12
Change from Baseline in health-related quality of life as measured by the 12-Item Short Form Health Survey (SF-12)
Time frame: Baseline and Month 12
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From baseline up to Month 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
Related trials for Hip OA
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
Osteoarthritis, Hip, Hip Osteoarthritis
Recruiting
Effects of EDUcation and EXercise Compared to Education Alone on Clinical and Physiological Outcomes in Patients With Hip Osteoarthritis
Hip Osteoarthritis
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hospital Universitario de La Princesa
Madrid, Spain
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hip OA, run by Meiji Pharma Spain S.A. at 4 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in self-reported hip pain severityu as measured by Visual Analog Scale (VAS) Pain Score at 12 months (time frame: Baseline (pre-treatment), 3 months and 12 months post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.